secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001213900-26-037470
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics reports FY2025 net loss of $3.2M; secures up to $25M venture debt
--------------------------------------------------------------------------------

- Cash and equivalents $5.08M as of Dec 31, 2025, excludes $7M initial tranche from Avenue Capital facility.
- Net loss $3.19M vs $1.77M in 2024; G&A rose to $5.5M from $1.5M on public listing costs.
- Phase 2 trial of GX-03 for atopic dermatitis on track; topline results expected mid-2026.
- Appointed former CDC Director Dr. Robert Redfield and Martin Dewhurst (ex-McKinsey) to leadership/board.
- Entered global license, supply, and distribution agreement with Medline; revenue expected to begin late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026037470/0001213900-26-037470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026037470/ea0283795-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-037470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer